Search from website

Protein production

Leave your inquiry here:

Contact Lauri

Name(Required)

Mammalian recombinant protein production​

From simplest of human IgG’s to afucosylated bispecific antibodies up to recombinant growth factors — we have produced them all!

Icosagen provides recombinant protein production services, using proprietary mammalian cell-based QMCF Technology with animal-free components.

Why choose QMCF technology for protein production?

SCALABLE
PRODUCTION

WELL ESTABLISHED

Production volumes from 96-well plates to 100-liter scale.

FLEXIBLE
PURIFICATION

FLEXIBLE PURIFICATION

Capabilities to purify proteins without affinity tags in addition to normal affinity-based purifications.

NO TARGET
IS TOO
DIFFICULT

NO TARGET IS TOO DIFFICULT

From recombinant growth factor to afucosylated bispecific antibody – we have succesfully produced them all!

NATIVE
LIKE
PROTEINS

MAMMALIAN PTM PATTERNS

Use of CHO and HEK293 cells provide native-like post translational modifications necessary for biological functionality.

OUTSTANDING
SUPPORT

OUTSTANDING SUPPORT

We have an experienced and dedicated team of PhD level project managers and scientists with can-do spirit. We are quick to respond to your questions to offer the best service and support available.

GUARANTEED
QUALITY

LONG TRACK RECORD

More than 1500 proteins produced and purified annually. Wide array of modern analytical methods used throughout the production process to guarantee consistent high quality.
0
Proteins produced annually
0
Different proteins purified annually

Transient protein production with QMCF Technology

Our QMCF Technology is a fast and reliable transient mammalian expression system for recombinant protein production with high yields up to 1g/L.

QMCF utilizes genetic modifications that increase the expression vector copy-number while ensuring their even distribution during cell division, guaranteeing stable expression levels.

Produced recombinant proteins are suitable for various types of pre-clinical research from structural biology to drug discovery as well as for commercial diagnostic assays.

QMCF Protein production workflow

Production volumes range from 96-well plate to 50-litre scale. A wide array of current analytical methods and equipment used throughout the production process ensures consistent highest quality. 

A variety of protein purification capabilities are established, ranging form affinity-based purifications to tagless proteins. 

With our technology, VLPs can be produced in HEK293-based QMCF
cell lines and purified by precipitation and/or density gradient fractionation.

Virus-Like Particles for Membrane Protein Expression

Transmembrane proteins, such as GPCRs, ion channels, and transporters are notoriously difficult to purify since they require the cell membrane lipid bilayer to maintain their native, active 3D-fold. The discovery of antibodies against such transmembrane proteins proved therefore very difficult in the past. GPCRs for example, are the largest class of cell-surface proteins that are targeted by almost 40% of all marketed drugs, but these are all small molecule drugs.


Icosagen has overcome this challenge by developing a proprietary pseudotyped VLP technology platform to conduct antibody discovery projects in-house on transmembrane proteins. We can produce transmembrane proteins in the context of virus-like particles (VLPs), using our QMCF mammalian expression platform. The co-expression of a viral envelope or capsid protein together with the transmembrane protein results in the self-assembly of pseudotyped VLPs, which are enriched with the membrane protein of interest. These pseudotyped VLPs serve for immunization and are frequently used in antibody screening, vaccine development, and receptor function studies.

FUNCTIONAL &
ACTIVE FORM
TARGET

FUNCTIONAL AND ACTIVE FORM

Functional and active display of integral membrane proteins on VLP surface provides unique approach for antibody-drugging hard-to-express membrane proteins.

FAST
AND
EFFICIENT

FAST AND EFFICIENT

Production of GPCRs, ion channels, transporters, viral glycoproteins etc.

HUMAN-
SPECIFIC
PTM

HUMAN-SPECIFIC POST-TRANSLATIONAL MODIFICATIONS

Using HEK293-based expression cell line.

ADCC Potency Enhancement via Afucosylation

Icosagen has a long-standing partnership with ProBioGen to use its GlymaxX® technology for generating fully afucosylated and therefore ADCC-enhanced antibodies. We offer rapid, multi-parallel, transiently produced ADCC-enhanced mAbs to assess cell-killing potency enhancement effects on any antibody.

GlymaxX®  is universally applicable, guarantees over 95% afucosylation and can be rapidly applied into existing production cell lines or to  new antibody development projects. Production timelines and final yields are identical for both regular and afucosylated antibodies.

Therapeutic antibodies with low fucose content have shown 10-100 fold higher antibody-dependent cellular cytotoxicity (ADCC) and thus drastically higher target cell killing potency. The degree of afucosylation levels can even be adjusted, hence the cell killing potency as well.

 

FAST AND
EASILY
APPLICABLE

FAST AND EASILY APPLICABLE

GlymaxX® is easily applicable to new and existing mAb clones. Production timelines remain constant.

CONSISTENT
PRODUCTION

PROVEN BATCH-TO-BATCH CONSISTENCY

Over 95% guaranteed mAb-afucosylation, every time. Re-addition of fucose to the medium allows gradually dialling back the degree of afucosylation levels to reduce and adjust potency.

POTENCY
INCREASE
STUDIES

POTENCY INCREASE STUDIES

Apply GlymaxX® and compare your mAb candidates potencies' in our in-house ADCC assays.
Antibody
development
Protein
production
Cell line
development
Analytics

For inquiries about protein production,
please contact Lauri Peil

Lauri Peil

Our locations

United States Office

77 Geary St. 5th Floor
San Francisco, CA 94108
+1 415 548 6625

European Office

Eerika tee 1
Õssu, Kambja vald
Tartu maakond 61713
Estonia
+372 737 7070
error:
Shopping Cart